As the founder of Atlanta’s renowned Busch Center, Dr. Joseph Busch Jr. brings a 40-year-plus track record in diagnostic radiology and hundreds of international research studies to preventative screening and accurate...
THIS WEEK'S FEATURE
MORE FEATURES
NEWS
Imara doses first patient in Phase 2b sickle cell disease trial
Imara (NASDAQ:IMRA) dosed the first patent in its Phase 2b Ardent trial evaluating IMR-687 for the treatment of sickle cell disease. The trial will enrol some 99 patients with sickle cell disease, who will receive...
Scholar Rock gets FDA rare pediatric disease designation for spinal muscular atrophy
Scholar Rock (NASDAQ:SRRK) received FDA rare pediatric disease designation for SRK-015 for the treatment of spinal muscular atrophy. Spinal muscular atrophy is a rare genetic disease that leads to motor function...
AzurRx BioPharma reports positive interim data from Phase 2 cystic fibrosis trial
AzurRx BioPharma (NASDAQ:AZRX) reported positive results from the first five patients in its Phase 2 combination therapy trial of MS1819 for the treatment of severe exocrine pancreatic insufficiency (EPI) in patients...
FDA approves Lantheus’ VIALMIXRFID activation device
The FDA approved Lantheus’ (NASDAQ:LNTH) supplemental drug application for VIALMIXRFID, a device that activates the company’s DEFINITY injectable suspension. DEFINITY injectable suspension is an ultrasound imaging agent...
Kane Biotech appoints renowned wound care and biofilms expert, Dr. Gregory Schultz, as scientific advisor
Kane Biotech (TSX-V:KNE) appointed wound care and biofilms expert, Dr. Gregory Schultz, as a scientific advisor. Dr. Schultz is the director of the Institute for Wound Research and professor of obstetrics and gynecology...
AGP ups Itamar Medical PT to $28 from $22.75
Alliance Global Partners raised its price target for Itamar Medical (NASDAQ:ITMR) to $28 from $22.75 after the company’s second quarter results beat expectations. However, the stock closed at $22.02, down $3.84, on Aug...
Hepion CRV431 antiviral benefits published in PLOS ONE
Hepion Pharmaceuticals (NASDAQ:HEPA) reported that the peer-reviewed journal, PLOS ONE, has published a paper highlighting the antiviral effects of CRV431. Co-authored by Hepion’s CSO, Dr. Daren Ure and CEO...
BTIG ups Sensenonics to buy; PT to $1
BTIG upgraded Sensenonics Holdings (NYSE American:SENS) to “buy” from “neutral” with a price target of $1, citing a commercial collaboration with Ascensia Diabetes Care, a financing agreement with Ascensia’s parent, PHC...
Ocugen OCU400 gets fourth FDA orphan drug designation for retinal disease
Ocugen’s (NASDAQ:OCGN) OCU400 received FDA orphan drug designation for the treatment of PDE6B gene mutation-associated retinal disease. OCU400 consists of a nuclear hormone receptor gene, NR2E3, which is delivered to...
Omeros reports positive results from COVID-19-associated ARDS trial
Omeros (NASDAQ:OMER) reported positive results from a study evaluating narsoplimab for the treatment of COVID-19-associated acute respiratory distress syndrome (ARDS). Narsoplimab is a human monoclonal antibody that is...
IBIO-201 demonstrates ability to elicit anti-SARS-CoV-2 immune response in preclinical studies
iBio (NYSE AMERICAN:IBIO) reported initial results from preclinical studies of IBIO-201, one of its two COVID-19 vaccine candidates. IBIO-201 is a subunit vaccine that combines antigens derived from the SARS-CoV-2 spike...
Seres SER-109 meets primary endpoint in Phase 3 study of C. difficile infection
Seres Therapeutics (NASDAQ:MCRB) reported positive topline results from its Phase 3 trial evaluating SER-109 for the treatment of recurrent C. difficile infection. The study enrolled 182 patients with multiply...
Just a few of the companies we’ve highlighted along the way
